These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 29205157)

  • 1. A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial.
    Iglesias JF; Muller O; Zaugg S; Roffi M; Kurz DJ; Vuilliomenet A; Weilenmann D; Kaiser C; Tapponnier M; Heg D; Valgimigli M; Eeckhout E; Jüni P; Windecker S; Pilgrim T
    EuroIntervention; 2018 Aug; 14(6):692-699. PubMed ID: 29205157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.
    Iglesias JF; Muller O; Heg D; Roffi M; Kurz DJ; Moarof I; Weilenmann D; Kaiser C; Tapponnier M; Stortecky S; Losdat S; Eeckhout E; Valgimigli M; Odutayo A; Zwahlen M; Jüni P; Windecker S; Pilgrim T
    Lancet; 2019 Oct; 394(10205):1243-1253. PubMed ID: 31488372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complex primary percutaneous coronary intervention with ultrathin-strut biodegradable versus thin-strut durable polymer drug-eluting stents in patients with ST-segment elevation myocardial infarction: A subgroup analysis from the BIOSTEMI randomized trial.
    Iglesias JF; Muller O; Losdat S; Roffi M; Kurz DJ; Weilenmann D; Kaiser C; Heg D; Windecker S; Pilgrim T
    Catheter Cardiovasc Interv; 2023 Mar; 101(4):687-700. PubMed ID: 36807456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial.
    Pilgrim T; Muller O; Heg D; Roffi M; Kurz DJ; Moarof I; Weilenmann D; Kaiser C; Tapponnier M; Losdat S; Eeckhout E; Valgimigli M; Jüni P; Windecker S; Iglesias JF
    JACC Cardiovasc Interv; 2021 Mar; 14(6):639-648. PubMed ID: 33727005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial.
    Iglesias JF; Muller O; Losdat S; Roffi M; Kurz DJ; Weilenmann D; Kaiser C; Heg D; Valgimigli M; Windecker S; Pilgrim T
    Int J Cardiol; 2021 Jul; 334():37-41. PubMed ID: 33887341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial.
    Zbinden R; Piccolo R; Heg D; Roffi M; Kurz DJ; Muller O; Vuilliomenet A; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Franzone A; Eberli F; Jüni P; Windecker S; Pilgrim T
    J Am Heart Assoc; 2016 Mar; 5(3):e003255. PubMed ID: 26979080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.
    Pilgrim T; Heg D; Roffi M; Tüller D; Muller O; Vuilliomenet A; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Fahrni T; Moschovitis A; Noble S; Eberli FR; Wenaweser P; Jüni P; Windecker S
    Lancet; 2014 Dec; 384(9960):2111-22. PubMed ID: 25189359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial.
    Iglesias JF; Roffi M; Losdat S; Muller O; Degrauwe S; Kurz DJ; Haegeli L; Weilenmann D; Kaiser C; Tapponnier M; Cook S; Cuculi F; Heg D; Windecker S; Pilgrim T
    Lancet; 2023 Nov; 402(10416):1979-1990. PubMed ID: 37898137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents.
    Iglesias JF; Heg D; Roffi M; Tüller D; Lanz J; Rigamonti F; Muller O; Moarof I; Cook S; Weilenmann D; Kaiser C; Cuculi F; Valgimigli M; Jüni P; Windecker S; Pilgrim T
    J Am Heart Assoc; 2019 Nov; 8(22):e013607. PubMed ID: 31696762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction.
    Pilgrim T; Piccolo R; Heg D; Roffi M; Tüller D; Vuilliomenet A; Muller O; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Khattab AA; Taniwaki M; Rigamonti F; Nietlispach F; Blöchlinger S; Wenaweser P; Jüni P; Windecker S
    EuroIntervention; 2016 Dec; 12(11):e1343-e1354. PubMed ID: 26690319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients.
    Roguin A; Kandzari DE; Marcusohn E; Koolen JJ; Doros G; Massaro JM; Garcia-Garcia HM; Bennett J; Gharib EG; Cutlip DE; Waksman R
    Circ Cardiovasc Interv; 2018 Oct; 11(10):e007331. PubMed ID: 30354631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: rationale and design of the BIOSCIENCE trial.
    Pilgrim T; Roffi M; Tüller D; Muller O; Vuilliomenet A; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Heg D; Jüni P; Windecker S
    Am Heart J; 2014 Sep; 168(3):256-61. PubMed ID: 25173535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial.
    Kandzari DE; Koolen JJ; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
    JACC Cardiovasc Interv; 2020 Jun; 13(11):1343-1353. PubMed ID: 32499026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial.
    Iglesias JF; Heg D; Roffi M; Tüller D; Noble S; Muller O; Moarof I; Cook S; Weilenmann D; Kaiser C; Cuculi F; Häner J; Jüni P; Windecker S; Pilgrim T
    Circ Cardiovasc Interv; 2019 Aug; 12(8):e008024. PubMed ID: 31525083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents: BIOFLOW V Final 5-Year Outcomes.
    Kandzari DE; Koolen JJ; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
    JACC Cardiovasc Interv; 2022 Sep; 15(18):1852-1860. PubMed ID: 36137689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents.
    Kandzari DE; Koolen JJ; Doros G; Massaro JJ; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
    J Am Coll Cardiol; 2018 Dec; 72(25):3287-3297. PubMed ID: 30257191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization.
    Yamaji K; Zanchin T; Zanchin C; Stortecky S; Koskinas KC; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Valgimigli M; Billinger M; Pilgrim T; Heg D; Windecker S; Räber L
    Circ Cardiovasc Interv; 2018 Sep; 11(9):e006741. PubMed ID: 30354590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrathin-strut vs thin-strut drug-eluting stents for multi and single-stent lesions: A lesion-level subgroup analysis of 2 randomized trials.
    Häner JD; Rohla M; Losdat S; Iglesias JF; Muller O; Eeckhout E; Kurz D; Weilenmann D; Kaiser C; Tapponnier M; Roffi M; Heg D; Windecker S; Pilgrim T
    Am Heart J; 2023 Sep; 263():73-84. PubMed ID: 37192697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial.
    Pilgrim T; Piccolo R; Heg D; Roffi M; Tüller D; Muller O; Moarof I; Siontis GCM; Cook S; Weilenmann D; Kaiser C; Cuculi F; Hunziker L; Eberli FR; Jüni P; Windecker S
    Lancet; 2018 Sep; 392(10149):737-746. PubMed ID: 30170848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial.
    Franzone A; Pilgrim T; Heg D; Roffi M; Tüller D; Vuilliomenet A; Muller O; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Räber L; Stortecky S; Wenaweser P; Jüni P; Windecker S
    Circ Cardiovasc Interv; 2015 Jun; 8(6):. PubMed ID: 26043895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.